Evropska unija - švedščina - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - hemostatika - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

biomedica foscama industria chimico farmaceutica spa - sertralinhydroklorid - filmdragerad tablett - 100 mg - laktosmonohydrat hjälpämne; sertralinhydroklorid 111,9 mg aktiv substans - sertralin

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

biomedica foscama industria chimico farmaceutica spa - sertralinhydroklorid - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; sertralinhydroklorid 55,95 mg aktiv substans - sertralin

Evropska unija - švedščina - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofili a - hemostatika - behandling och profylax av blödning hos patienter med hemofili a (medfödd faktor viii-brist). denna beredning innehåller inte von willebrand-faktorn och är därför inte anges i von willebrands sjukdom.

Evropska unija - švedščina - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofili a - hemostatika - behandling och profylax av blödning hos patienter med hemofili a (medfödd faktor viii-brist). iblias kan användas för alla åldersgrupper.

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rivaroxaban - filmdragerad tablett - 2,5 mg - rivaroxaban 2,5 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

orion corporation - rivaroxaban - filmdragerad tablett - 2,5 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; rivaroxaban 2,5 mg aktiv substans

Švedska - švedščina - Läkemedelsverket (Medical Products Agency)

cipla europe nv - bivalirudin - pulver till koncentrat till injektions-/infusionsvätska, lösning - 250 mg - bivalirudin 250 mg aktiv substans; mannitol hjälpämne

Evropska unija - švedščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiska medel - förebyggande av venös tromboembolism (vte) hos vuxna patienter som genomgår elektiv höft- eller knäbytesoperation. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 för hemodynamiskt instabila pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 och 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling av djup ventrombos (dvt) och lungemboli (pe), och förebyggande av återkommande dvt och pe i vuxna. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropska unija - švedščina - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.